U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07170787) titled 'A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors' on Sept. 02.
Brief Summary: This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant protein) combine with IMM01(Anti-CD47 Recombinant Protein) in patients with advanced solid tumors who have received at least first line treatment in past.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
BIOLOGICAL: IMM2510
IMM2510 administered...